First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Average Rating of “Buy” from Brokerages

First Tracks Biotherapeutics (NASDAQ:TRAX) has been assigned a consensus recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have covered the stock in the last year is $38.40.

A number of equities research analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of First Tracks Biotherapeutics in a report on Friday. They set an “outperform” rating and a $46.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of First Tracks Biotherapeutics in a report on Thursday, April 23rd. They set an “overweight” rating and a $31.00 price objective for the company. Wedbush started coverage on shares of First Tracks Biotherapeutics in a report on Friday. They set an “outperform” rating and a $30.00 price objective for the company. HC Wainwright started coverage on shares of First Tracks Biotherapeutics in a research report on Tuesday. They issued a “buy” rating and a $30.00 price target for the company. Finally, Barclays started coverage on shares of First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 price target for the company.

First Tracks Biotherapeutics Price Performance

Shares of TRAX opened at $18.10 on Tuesday. First Tracks Biotherapeutics has a 1-year low of $14.79 and a 1-year high of $26.80.